While not yet mainstream in the community setting, measurable residual disease (MRD) testing has the potential to become more fully integrated into clinical practice as one of the reliable markers of treatment response for patients with multiple myeloma and chronic lymphocytic leukemia.

Our guests—Drs. Rafael Fonseca and Tara Graff—discuss the benefits of MRD testing for these specific patient populations, the importance of training the multidisciplinary care team, and the promise of MRD testing to improve patient outcomes as its adoption continues to grow.

Guests:

Rafael Fonseca, MD

Professor of Medicine, Mayo Clinic

Scottsdale, Arizona

Tara Graff, DO

Medical Oncologist, Mission Cancer and Blood

Des Moines, Iowa

This podcast is produced as part of the ACCC MRD Testing Implementation Roadmaps education project and is funded by Adaptive Biotechnologies.

Resources:

• MRD Testing Implementation Roadmaps
• MRD Testing Implementation Roadmap for B-cell Acute Lymphoblastic Leukemia
• MRD Testing Resource Library
• Multidisciplinary Multiple Myeloma Care
• Biomarkers in Hematologic Malignancies: A Focus on CLL and Multiple Myeloma
• Multidisciplinary Chronic Lymphocytic Leukemia Care